AASK 队列研究-猫眼课题宝

AASK 队列研究

批准号：

7489782

负责人：

DEANNA E. CHEEK

金额：

$5.47万

依托单位：

MEDICAL UNIVERSITY OF SOUTH CAROLINA

依托单位国家：

美国

项目类别：

财政年份：

1994

资助国家：

美国

项目状态：

已结题

起止时间：

1994-08-15 至 2008-06-30

来源：

https://reporter.nih.gov/project-details/7489782

关键词：

Address African American American Antihypertensive Agents Appendix Biological Blood Pressure Cardiovascular Diseases Cardiovascular system Caring Cessation of life Cheek structure Child Chronic Kidney Failure Chronic Kidney Insufficiency Clinical Trials Cohort Studies Communities DNA Data Data Collection Development Development Plans Disease Outcome Disease Progression Echocardiography Economic Factors End Point End stage renal failure Enrollment Face Foundations Genetic Goals Guidelines Hospitalization Hypertension Instruction Intervention Trial Kidney Kidney Diseases Kidney Failure Letters Literature Long-Term Effects Manuscripts Measurement Measures Medical Records Metabolic Methods Minority Monitor Morbidity - disease rate Nephrosclerosis Numbers Outcome Outcome Study Participant Patients Pattern Persons Pharmaceutical Preparations Phase Physiological Plasma Population Principal Investigator Progress Reports Proteinuria Protocols documentation Publications Publishing Questionnaires Randomized Randomized Controlled Clinical Trials Rate Renal function Research Research Design Resources Risk Risk Factors Safety Shipping Ships Specimen Standards of Weights and Measures Structure of nail of finger Urine Vertebrates Woman base blood pressure regulation clinical Diagnosis clinical research site cohort computerized data processing data management follow-up human subject mortality programs prospective trial comparing

项目摘要

项目成果

DEANNA E. CHEEK的其他基金

相似基金

相关文献

中文摘要

翻译

........... 6 3 其他个人简介（每份不超过四页-见说明）... 7 2 资源...... 8 1 入组表... 9 1 研究计划页码_ 1 修订申请简介（不超过3页）.... 补充申请简介（不超过一页）....... 10 2 a.具体目标....... _,_. .................................................................................... __. B。背景和意义....... | .................................................................................... I "11 1 C.初步研究/进度报告/（项目A-D.不超过25页 *）。12 1 B 第I阶段进度报告（仅限SBIR/STTR第II阶段）|* SBIR/STTR阶段h项目A-D限制为15页B。我 D.研究设计和方法..... J........¿ 13 5 e.人类受试者................................................................................................................................................................. 14 1 人类受试者保护（如果正面页面上的第4项标记为"是"，则需要）14 1 纳入女性（如果正面页面上的项目4标记为"是"，则需要）... 14 1 纳入少数群体（如果正面页项目4标记为"是"，则需要）.... 14 1 纳入儿童（如果正面页上的第4项标记为"是"，则需要）..... 14 1 数据和安全性监测计划（如果正面页面上的第4项标记为"是"，则需要，并且是I期、II期或III期临床试验建议试用...................................................................................................................................................... 14 1 F.脊椎动物............................................................................................................................................................. 15 1 G.引用的文献................................................................................................................................................................... 15 1 H.联合体/合同安排...... n/a I.支持信（例如，顾问）... n/a J.产品开发计划（仅限SBIR/S-I-FR第二阶段和快速通道）... n/a 核对表.. 16 1 附录（五个整理集。附录无需页码。）检查是否阑尾是包括附录不允许用于I期SBIR/STTR，除非特别要求。接受出版的出版物和手稿数量（不超过10份）其他项目（列表）： PHS 398（修订版05/01）第3页表格第3页

英文摘要

........... 6 3 Other Biographical Sketches (Not to exceed four pages for each - See instructions)) ........................ 7 2 Resources .................................................................................................................................................. 8 1 Enrollment Table ...................................................................................................................................... 9 1 Research Plan Page Numbe_ 1 Introduction to Revised Application (Not to exceed 3 pages) ......................................................................................................... Introduction to Supplemental Application (Not to exceed one page) .............................................................................................. 10 2 A. Specific Aims ......................................................................... _,_. .................................................................................... __. B. Background and Significance .................................................... | .................................................................................... I" 11 1 C. Preliminary Studies/Progress Report/ _ (Items A-D. not to exceed 25 pages*) .,_ 12 1 B Phase I Progress Report (SBIR/STTR Phase II ONLY) | * SBIR/STTR Phase h Items A-D limited to 15 pageB s. I D. Research Design and Methods .....................................................J.................................................................................. ¿ 13 5 E. Human Subjects ................................................................................................................................................................. 14 1 Protection of Human Subjects (Required if Item 4 on the Face Page is marked "Yes") 14 1 Inclusion of Women (Required if Item 4 on the Face Page is marked "Yes") ................................................................. 14 1 Inclusion of Minorities (Required if Item 4 on the Face Page is marked "Yes") ............................................................... 14 1 Inclusion of Children (Required if Item 4 on the Face Page is marked "Yes") ................................................................. 14 1 Data and Safety Monitoring Plan (Required if Item 4 on the Face Page is marked "Yes" and a Phase 1, II, or Ill clinical trial is proposed ...................................................................................................................................................... 14 1 F. Vertebrate Animals ............................................................................................................................................................. 15 1 G. Literature Cited ................................................................................................................................................................... 15 1 H. Consortium/Contractual Arrangements ............................................................................................................................... N/a I. Letters of Support (e.g., Consultants) ................................................................................................................................. N/a J. Product Development Plan (SBIR/S-I-FR Phase II and Fast-Track ONLY) .......................................................................... N/a Checklist .................................................................................................................................................... 16 1 Appendix (Five collated sets. No page numbering necessary for Appendix.) Check if Appendix is Included Appendices NOT PERMITTED for Phase I SBIR/STTR unless specifically solicited. Number of publications and manuscripts accepted for publication (not to exceed 10) Other items (list): PHS 398 (Rev. 05/01) Page 3 Form Page 3

期刊论文(0)

专著(0)

科研奖励(0)

会议论文